Pharma industry outlook in 2018 What will be the key trends shaping the pharmaceutical industry in 2018? DCAT Value Chain Insights takes an inside look
What will be the key trends shaping the pharmaceutical industry in 2018? Top issues to watch for in 2018 include: mergers and acquisitions (M&A), driven in part by US tax reform, continued strength in venture-capital funding, and further product innovation following a 21-year high in US FDA approvals of new molecular entities in 2017.
From increased mergers and acquisitions (M&A), driven in part by US tax reform, to continued strength in venture capital funding, 2018 is expected to see increased M&A activity and continued strength from both private and public financing. What else may be in store?
TOP 10 ISSUES FOR 2018
1. Mergers and acquisitions in 2018. Led by a bullish stock market and US corporate tax form, some analysts are projecting a robust year in 2018 for mergers and acquisitions (M&A). According to EP Vantage, the editorial arm of Evaluate Ltd., 2018 could be a strong year for M&A in the pharmaceutical industry driven by both Big Pharma’s and Big Biotech’s need to restock and strengthen pipelines.
In terms of M&A, corporate taxation was a major impetus behind several recent high-profile deals that were in part sought for financial reasons to achieve an improved tax position through corporate inversion. A corporate inversion occurs when a US-based multinational corporation restructures itself so that the US parent is replaced by a foreign parent and the original US company becomes a subsidiary of ...